[go: up one dir, main page]

KR950007855A - 정맥내 주사용 라파마이신 제형 - Google Patents

정맥내 주사용 라파마이신 제형 Download PDF

Info

Publication number
KR950007855A
KR950007855A KR1019940024426A KR19940024426A KR950007855A KR 950007855 A KR950007855 A KR 950007855A KR 1019940024426 A KR1019940024426 A KR 1019940024426A KR 19940024426 A KR19940024426 A KR 19940024426A KR 950007855 A KR950007855 A KR 950007855A
Authority
KR
South Korea
Prior art keywords
rapamycin
solution
concentration
concentrate
propylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019940024426A
Other languages
English (en)
Other versions
KR100376192B1 (ko
Inventor
폴 워래니스 로버트
웨이몬드 레오나드 토마스
Original Assignee
에곤 이. 버그
아메리칸 홈 프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에곤 이. 버그, 아메리칸 홈 프로덕츠 코포레이션 filed Critical 에곤 이. 버그
Publication of KR950007855A publication Critical patent/KR950007855A/ko
Application granted granted Critical
Publication of KR100376192B1 publication Critical patent/KR100376192B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 라파마이신 농도가 0.25 내지 8㎎/㎖인 프로필렌 글리콜중 라파마이신 농축액 40내지 75용적%와 혼합 용액의 60 대지 25용적%를 구성하는 물을 포함한 희석제 용액을 주사용액중 라파마이신 농도가 0.1 내지 4㎎/㎖가 되도록 혼합함으로써 수득되는 주사용 라파마이신 수용액에 관한 것이다.

Description

정맥내 주사용 라파마이신 제형
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 라파마이신 농도가 0.25 내지 8㎎/㎖인 프로필렌글리콜중 라파마이신 농축액 40 내지 75용적%와 혼합용액의 60내지 25용적%를 구성하는 물을 포함한 희석제 용액을 주사용액중 라파마이신 농도가 0.1 내지 4㎎/㎖가 되도록 혼합함으로써 수득되는 주사용 라파마이신 수용액.
  2. 제1항에 있어서, 프로필렌 글리콜중 라파마이신 농축액이 주사용액이 40 내지 60용적%를 구성하는 주사용 라파마이신 수용액.
  3. 제1항 모는 제2항에 있어서, 프로필렌 글리콜중 라파마이신의 농도가 0.5 내지 4㎎/㎖인 프로필렌글리콜중 라파마이신 수용액.
  4. 라파마이신 농도가 0.5 내지 4㎎/㎖인 프로필렌글리콜중 라파마이신 농축액 40 내지 60용적%와 혼합용액의 60 내지 40용적%를 구성하는 물을 포함한 희석제 용액을 주사용액중 라파마이신 농도가 0.25 내지 2㎎/㎖가 되도록 혼합함으로써 수득되는 주사용 라파마이신 수용액.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, 프로필렌 글리콜중 라파마이신 농축액이 주사용액의 40 내지 50용적%를 구성하는 주사용 라파마이신 수용액.
  6. 제1항 내지 제5항중 어느 한 항에 있어서, 프로플렌 글리콜중 라파마이신 농도가 0.6 내지 3.3㎎/㎖인 주사용 라파마이신 수용액.
  7. 제1항 내지 제6항중 어느 한 항에 있어서, 주사용액중 라파마이신 농도가 0.5내지 1.5㎎/㎖인 주사용 라파마이신 수용액.
  8. 제1항에 있어서, 주사용액중 라파마이신 농도가 0.25 내지 2㎎/㎖인 농축과 주사용 라파마이신 수용액.
  9. 물이 용액의 40 내지 75용적%를 구성하고 용액중 라파마이신 농도가 0.1 내지 4㎎/㎖인, 프로필렌 글리콜 및 물의 용액중 라파마이신을 포함하는 주사용 라파마이신 수용액.
  10. 농축액은 프로필렌 글리콜중 라파마이신을 0.25 내지 8㎎/㎖로 포함하며 희석 용액은 40 : 60 내지 75 : 25용적%의 농축액 : 희석제의 비로 물을 포함하는, 정맥내 투여 전에 혼합하여 라파마이신 농도가 0.1 내지 4㎎/㎖인 용액을 제조하기 위한 혼합제제로서 라파마이신과 희석제의 농축액을 함유하는 생성물.
  11. 제10항에 있어서, 농축액 : 희석제의 비가 60 : 40 내지 40 : 60인 생성물.
  12. 제10항 또는 제11항에 있어서, 프로필렌 글리콜 농축액중 라파마이신 농도가 0.5 내지 4㎎/㎖인 생성물.
  13. 제10항에 있어서, 희석제와 혼합시에 라파마이신 농도가 0.25 내지 2㎎/㎖인 농축과 주사용 생성물.
  14. 농축액은 프로필렌 글리콜중 라파마이신을 0.5 내지 4㎎/㎖로 포함하여 희석 용액은 40 : 60 내지 75 : 25용적%의 농축액 : 희석제의 비로 물을 포함하는, 정맥내 투여 전에 혼합하여 라파마이신 농도가 0.1 내지 4㎎/㎖인용액을 제조하기 위한 혼합제제로서 라파마이신과 희석제의 농축액을 함유하는 생성물.
  15. 라파마이신 농도가 0.25 내지 8㎎/㎖인 프로필렌 글리콜 중 라파마이신 농축액 40 내지 75용적%와 혼합용액의 60 내지 25용적%를 구성하는 물을 포함한 희석제 용액을 주사용액중 라파마이신 농도가 0.1 내지 4㎎/㎖가 되도록 혼합함으로써 주사용 라파마이신 수용액을 제조하는 방법.
  16. 제15항에 있어서, 프로필렌 글리콜중 라파마이신 농축액이 주사용액의 40 내지 60용적%를 구성하는 방법.
  17. 제15항 또는 제16항에 있서, 프로필렌 글리콜중 라파마이신 농도가 0.5 내지 4㎎/㎖인 방법.
  18. 라파마이신 농도가 0.5 내지 4㎎/㎖인 프로필렌글리콜중 라파마이신 농축액 40 내지 60용적%와 혼합용액의 60 내지 40용적%를 구성하는 물을 포함한 희석제 용액을 주사용액중 라파마이신 농도가 0.25 내지 2㎎/㎖가 되도록 혼합함으로써 주사용 라파마이신 수용액을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940024426A 1993-09-30 1994-09-28 정맥내주사용라파마이신제형및이의제조방법 Expired - Fee Related KR100376192B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12952693A 1993-09-30 1993-09-30
US08/129526 1993-09-30
US08/129,526 1993-09-30
US08/302190 1994-09-12
US08/302,109 1994-09-12
US08/302,190 US5616588A (en) 1993-09-30 1994-09-12 Rapamycin formulation for IV injection

Publications (2)

Publication Number Publication Date
KR950007855A true KR950007855A (ko) 1995-04-15
KR100376192B1 KR100376192B1 (ko) 2005-08-18

Family

ID=22440429

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940024426A Expired - Fee Related KR100376192B1 (ko) 1993-09-30 1994-09-28 정맥내주사용라파마이신제형및이의제조방법

Country Status (11)

Country Link
US (1) US5616588A (ko)
EP (1) EP0650729B1 (ko)
KR (1) KR100376192B1 (ko)
AT (1) ATE172120T1 (ko)
AU (1) AU689488B2 (ko)
DE (1) DE69413923T2 (ko)
DK (1) DK0650729T3 (ko)
ES (1) ES2123721T3 (ko)
FI (1) FI944537A7 (ko)
HU (1) HU219236B (ko)
SG (1) SG47715A1 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100562800B1 (ko) * 2004-04-26 2006-03-23 이영기 소형 전기세탁기용 탈수통 클러치장치
KR20150090583A (ko) * 2014-01-29 2015-08-06 삼성전자주식회사 세탁기 및 그 제어방법

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
CN1222529C (zh) 2000-09-19 2005-10-12 惠氏公司 水溶性雷怕霉素酯类
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
CA2493878C (en) 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
US8163726B2 (en) * 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
ES2527055T3 (es) * 2004-07-30 2015-01-20 Novartis Ag Formulaciones de compuestos 2-amino-1,3-propanodiol
US20060258698A1 (en) 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
KR101267813B1 (ko) 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
US20200397763A1 (en) 2018-02-23 2020-12-24 Biotronik Ag Parenteral formulation materials and methods for 40-o-cyclic hydrocarbon esters and related structures

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH0734373B2 (ja) * 1989-11-15 1995-04-12 ヒロセ電機株式会社 コネクタ
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
HUT70947A (en) * 1992-03-30 1995-11-28 American Home Prod Injectable rapamycin solutions and process for producing them
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100562800B1 (ko) * 2004-04-26 2006-03-23 이영기 소형 전기세탁기용 탈수통 클러치장치
KR20150090583A (ko) * 2014-01-29 2015-08-06 삼성전자주식회사 세탁기 및 그 제어방법

Also Published As

Publication number Publication date
FI944537A0 (fi) 1994-09-29
AU7435394A (en) 1995-04-13
HU219236B (en) 2001-03-28
KR100376192B1 (ko) 2005-08-18
ATE172120T1 (de) 1998-10-15
DK0650729T3 (da) 1999-06-23
SG47715A1 (en) 1998-04-17
HK1012230A1 (en) 1999-07-30
DE69413923D1 (de) 1998-11-19
HUT71101A (en) 1995-11-28
EP0650729B1 (en) 1998-10-14
US5616588A (en) 1997-04-01
FI944537L (fi) 1995-03-31
FI944537A7 (fi) 1995-03-31
DE69413923T2 (de) 1999-05-12
EP0650729A1 (en) 1995-05-03
AU689488B2 (en) 1998-04-02
HU9402808D0 (en) 1995-01-30
ES2123721T3 (es) 1999-01-16

Similar Documents

Publication Publication Date Title
KR950007855A (ko) 정맥내 주사용 라파마이신 제형
KR950007858A (ko) 정맥내 주사용 라파마이신 제형
TW427903B (en) Rapamycin formulation for IV injection
BR0206511A (pt) Formulação parenteral para análogos de epotilona
BR0206509A (pt) Métodos de administração de análogos de epotilona para o tratamento de câncer
DK0674510T3 (da) Injicerbart præparat omfattende paclitaxel
JPS6485921A (en) Cyclosporin preparation
ES2157686T3 (es) Nanoemulsion a base de citratos de alquileter y sus utilizaciones en los ambitos cosmetico, dermatologico, farmaceutico y/o oftalmico.
KR850004391A (ko) 비-수성 아이버멕틴 제형
KR910011250A (ko) 향정신성 약물의 안정화 용액
KR890015745A (ko) 수용액으로 존재하는 피록시캄의 제약 조성물 및 그의 제조방법
FI940696A0 (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
US2407624A (en) Aqueous solution of riboflavin
DE3671168D1 (de) Pharmazeutische zubereitung.
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
JPS57200361A (en) "indomethacin(r)" pharmaceutical with low irritant action
CA2534259A1 (en) Glycyrrhizin high-concentration preparation
ES2124414T3 (es) Solucion inyectable destinada a la administracion intramuscular y subcutanea en animales.
KR890007731A (ko) 생물학적으로 매우 유용한 형태의 철을 함유한 단백질 유도체, 그의 제조 및 이 화합물을 함유하는 제약 조성물
KR910019605A (ko) 항진균성 겔제
DK1369122T3 (da) Anticancermiddel
KR910004668A (ko) 해파린상 구조를 지닌 물질 및 이의 제조방법
KR940006488A (ko) 영양 조성물 및 이의 제조방법
JPS55149208A (en) Stabilization of biologically active substances with solid acid and base
TH62366A (th) สารผสมปฏิชีวนะแอซะไลด์

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19940928

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990715

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19940928

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20011031

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20021226

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20030304

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20030305

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20070210